CTC significance in clinical application has been proven by several studies. CTC isolated with ISET® technology can be useful in follow-up, assessment and therapy management and for any solid cancer. Here we present the latest innovations in early detection for invasive cancers, the prognostic value of CTC isolated by ISET®, and feasability for non invasive and immuno-theranostic.
The ISET® technology is so flexible, it is not only capable of filtering human blood but also blood from many animal models. So far, blood samples from mouse, rat (Lelièvre L. et al, Int J Gynecol Cancer 2004), pig, dog, horse and chimpanzee have been treated using the ISET® technology.
The ISET® Device is an in vitro medical device ensuring the enrichment of CTC present in the blood by vertical and efficient filtration. It is mandatory to use the ISET® Device in combination with its associated consumables, specifically designed for the ISET® technique. The ISET® Device is equipped with a digital gauge displaying depression, two independent filtration stations generating a gentle vacuum-dependant aspiration (-10 mbar to -300 mbar) for filtering two 10 mL samples at the same time, a movable cover and a knob permitting adjustments to get a constant vacuum filtration according to blood resistance and quality.
The Rarecells® block is a single-use consumable to be inserted in the Rarecells® device. It allocates 10 mL of blood diluted 1:10 with the Rarecells® buffer (thus a volume of 100 mL of diluted blood) for its standard use. The block allows filtering the diluted blood through 10 circular filtration areas (spots).
After filtration, each spot will contain the large cells which were, before filtration, in 1 mL of blood. [Read More..]
The role of this solution is to dilute blood samples in order to lysate red blood cells without damaging CTC or CTM, allowing filtration of the blood. [Read More…]
For more informations
- 10th Annual NGS & Clinical Diagnostics Congress – Attend the Scientific Presentation of Prof. Paterlini-Bréchot, Scientific Advisor of Rarecells Diagnostics – November the 9th, 2018 at 1:30 pm5 November 2018As invited speaker, Prof. Paterlini-Bréchot will attend the 10th Annual NGS & Clinical Diagnostics Congress in London with a presentation on the 9th of November, 2018 at 1:30 pm entitled [Read More...]
- SelectBio 2018 Liquid Biopsies & Exosomes Europe Conference – Attend the Scientific Presentation of Prof. Paterlini-Bréchot, Scientific Advisor of Rarecells Diagnostics – October the 24th, 2018 at 3:30 pm22 October 2018As invited speaker, Prof. Paterlini-Bréchot will attend the SelectBio 2018 Liquid Biopsies & Exosomes Europe Conference with a presentation on the 24th of October, 2018 at 3:30 pm entitled [Read More...]
- European Association of Nuclear Medicine Congress 2018 – Attend the Scientific Presentation of Prof. Paterlini-Bréchot, Scientific Advisor of Rarecells Diagnostics – October the 14th, 2018 at 5:15 pm12 October 2018As invited speaker, Prof. Paterlini-Bréchot will attend the 2018 Congress of the European Association of Nuclear Medicine (EANM’18) in the Joint-symposium ” New techniques for diagnosis [Read More...]